RxSight, Inc. (RXST) Q4 2025 Earnings Call Transcript

RxSight, Inc. (RXST) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 26, 2026

RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates

RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.03 per share a year ago.

Zacks Investment Research • Feb 26, 2026

Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Feb 18, 2026

RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

GlobeNewsWire • Feb 11, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST).  Such investors are advised to contact Danielle Peyton at [email protected]  or 646-581-9980, ext.

PRNewsWire • Jan 22, 2026

RxSight, Inc. (RXST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

RxSight, Inc. (RXST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Seeking Alpha • Jan 14, 2026

RxSight (RXST) Soars 14.1%: Is Further Upside Left in the Stock?

RxSight (RXST) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Zacks Investment Research • Jan 13, 2026

RxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial Officer

ALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition.

GlobeNewsWire • Jan 11, 2026

RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference

ALISO VIEJO, Calif., Jan. 02, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced plans to participate in the upcoming J.P. Morgan Healthcare Conference.

GlobeNewsWire • Jan 2, 2026

RxSight, Inc. Announces Chief Financial Officer Transition

ALISO VIEJO, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced that Shelley Thunen, the Company's Chief Financial Officer, is transitioning from her role. Ms. Thunen will remain with the Company until the sooner of the appointment of her successor or January 31, 2026. Ms. Thunen has agreed to support the Company as a consultant subsequent to the transition.

GlobeNewsWire • Dec 22, 2025